AKUMS

May 18 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• AKUMS DRUGS AND PHARMACEUTICALS LTD - RESUMES 100% OPERATIONS AT UTTARAKHAND SITES FROM MAY 18, 2026

• AKUMS DRUGS AND PHARMACEUTICALS LTD - PARTIAL DISRUPTION AT HARIDWAR SITES CAUSED 200 MILLION RUPEES DELAYED SUPPLY

Source text: ID:nNSE5QmDcP

Further company coverage: AKUM.NS

((Reuters.Briefs@thomsonreuters.com;))

May 14 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• AKUMS DRUGS AND PHARMACEUTICALS LTD - RECOMMENDS FINAL DIVIDEND OF 1 RUPEE AND SPECIAL DIVIDEND OF 2 RUPEES PER SHARE

• AKUMS DRUGS AND PHARMACEUTICALS MARCH-QUARTER CONSOL NET PROFIT 846.1 MILLION RUPEES

• AKUMS DRUGS AND PHARMACEUTICALS MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 11.58 BILLION RUPEES

Source text: ID:nNSE6PT8Zp

Further company coverage: AKUM.NS

((Reuters.Briefs@thomsonreuters.com;))

April 29 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• AKUMS DRUGS - EXECUTION OF LEASE DEED FOR UTTARAKHAND LAND

Source text: ID:nNSE1GKZvk

Further company coverage: AKUM.NS

((Reuters.Briefs@thomsonreuters.com;))

Feb 13 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• AKUMS DRUGS AND PHARMACEUTICALS DEC-QUARTER CONSOL NET PROFIT 663.2 MILLION RUPEES

• AKUMS DRUGS AND PHARMACEUTICALS DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.6 BILLION RUPEES

Source text: ID:nBSEb2HzYN

Further company coverage: AKUM.NS

((Reuters.Briefs@thomsonreuters.com;))

Jan 23 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• AKUMS DRUGS AND PHARMACEUTICALS LTD - RECEIVED EUROPEAN GMP CERTIFICATES FOR ITS TWO HARIDWAR FACILITIES

Source text: ID:nnAZN4S3PKC

Further company coverage: AKUM.NS

((Reuters.Briefs@thomsonreuters.com;))

Dec 25 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• UNIT GETS TOTAL TAX DEMAND ORDER OF 5.4 MILLION RUPEES

Source text: ID:nBSE5s9whP

Further company coverage: AKUM.NS

((Reuters.Briefs@thomsonreuters.com;;))

** Shares of Akums Drugs and Pharmaceuticals AKUM.NS rise 3.5% to 497 rupees

** Drugmaker posts 5.5% Y/Y rise in June-qtr consol net profit; consol rev from ops rises 0.5% Y/Y

** AKUM rated "strong buy" by 3 analysts on average; median target price is 710 rupees – data compiled by LSEG

** Stock down 22% YTD

(Reporting by Rudra Pratap Singh in Bengaluru)

((rudrapratap.singh@thomsonreuters.com))

** Shares of Akums Drugs AKUM.NS rise 2.1% to 519 rupees apiece

** Citi Research initiates coverage of the co, which is a contract development and manufacturing organisation (CDMO), with "buy"

** Brokerage sets PT of 700 rupees, implying a 12-month return of 37.8%

** Says AKUM has an edge over competition in terms of scale, manufacturing capabilities

** Adds recent weakness due to correction in the prices of active pharma ingredients (API) will be transient, expects recovery in fiscal 2026 and 2027

** AKUM's 100-million-euro CDMO contract from a global pharma company will aid earnings, showcases potential to make inroads in international markets, says Citi

** AKUM shares down 19% in 2025 so far, nearly twice as much as the 9.5% drop in Nifty 500 index .NIFTY500 - data compiled by LSEG

(Reporting by Bharath Rajeswaran in Bengaluru)

((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))

Jan 22 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• AKUMS DRUGS AND PHARMACEUTICALS - INCOME TAX DEPARTMENT CONDUCTS SEARCH AT AKUMS OFFICES AND UNITS

• AKUMS DRUGS AND PHARMACEUTICALS LTD - BUSINESS OPERATIONS CONTINUE AS USUAL WITH MINOR HICCUPS

Source text: ID:nBSE5577PC

Further company coverage: AKUM.NS

((reuters.briefs@thomsonreuters.com;))

Nov 26 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• AKUMS DRUGS - TIES UP WITH JAGDALE FOR MARKETING READY TO DRINK NUTRITIONAL BEVERAGES

Source text: ID:nBSE2tT0S5

Further company coverage: AKUM.NS

((Reuters.Briefs@thomsonreuters.com;))

Nov 19 (Reuters) - Caregen Co Ltd 214370.KQ:

• AKUMS DRUGS AND PHARMACEUTICALS - ENTERED INTO EXCLUSIVE MASTER SALES AGREEMENT WITH CAREGEN CO

• AKUMS DRUGS AND PHARMACEUTICALS - GRANTED EXCLUSIVE RIGHTS TO SELL CERTAIN CAREGEN PRODUCTS IN INDIA

Source text: ID:nBSE2tp8d

Further company coverage: 214370.KQ

((Reuters.Briefs@thomsonreuters.com;))

** Akums Drugs and Pharmaceuticals AKUM.NS rises as much as 5.5% to 929.10 rupees

** Co enters into license and distribution agreement with Canada-based Triple Hair, a biotechnology firm that specializes in developing therapies to curb hair loss

** Says AKUM granted exclusive rights to further develop and market products recently innovated by Triple Hair in India

** More than 218,000 shares traded, 1.1x the 30-day avg

** Since listing in August, AKUM has risen 27%

(Reporting by Ashish Chandra in Bengaluru)

((ashish.chandra@thomsonreuters.com (+91 7982114624))

Oct 9 (Reuters) - Akums Drugs and Pharmaceuticals Ltd AKUM.NS:

• LAUNCHES FAMOTIDINE, CALCIUM CARBONATE, MAGNESIUM HYDROXIDE IN INDIA

Source text for Eikon: ID:nNSE5PN7K9

Further company coverage: AKUM.NS

((Reuters.Briefs@thomsonreuters.com;;))